{
    "clinical_study": {
        "@rank": "147914", 
        "arm_group": {
            "arm_group_label": "HBsAg vaccine with Entecavir", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in\n      combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine."
        }, 
        "brief_title": "Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects who have been treated with HB110E 2mg or 4mg within 6 months prior to\n             screening.\n\n          -  positive HBsAg at screening\n\n          -  serum HBV DNA level below 300copies/mL at screening\n\n          -  ALT level within 2 x ULN at screening\n\n          -  voluntarily provide the informed consent\n\n        Exclusion Criteria:\n\n          -  participation in other study within 30 days of screening\n\n          -  subjects with severe allergic reaction or severe adverse event to HBsAg vaccine, or\n             not suitable for HBsAg vaccine.\n\n          -  any other conditions that are considered inappropriate for the study by the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813487", 
            "org_study_id": "HB110E_PI_PS"
        }, 
        "intervention": {
            "arm_group_label": "HBsAg vaccine with Entecavir", 
            "intervention_name": "HBsAg vaccine with Entecavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "137 701"
                }, 
                "name": "The Catholic University of Korea Seoul St. Mary's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy in Patients Who Have Been Treated With HB110E Hepatitis B DNA Vaccine", 
        "overall_official": {
            "affiliation": "The Catholic University of Korea", 
            "last_name": "Seung Yoon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "sample for immunologic assay will be collected at each visit; VS(~4week), VT1(0week), VT2(8week), VF(16week. T-cell response will be measured by ex-vivo & cultured ELISPOT.", 
            "measure": "Immunogenicity: HBV specific T-cell response by ELISPOT", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in HBV specificic T-cell response at 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "sample for HBsAg will be collected at each visit; VS(~4week), VT1(0week), VT2(8week), VF(16week. Change from baseline in HBsAg titer will be measured at VF.", 
            "measure": "HBsAg titer", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline in HBsAg titer at 16 weeks"
        }, 
        "source": "Genexine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genexine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}